MARKET

IVBIY

IVBIY

Innovent Biologi
OTCPK
21.00
NaN%
Closed 09:30 04/26 EDT
OPEN
--
PREV CLOSE
21.00
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
21.00
52 WEEK LOW
21.00
MARKET CAP
8.52B
P/E (TTM)
-56.5580
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at IVBIY last week (0415-0419)?
Weekly Report · 4d ago
Innovent Biologics appoints new oncology medical chief
Innovent Biologics appoints new oncology medical chief. Dr. Nageatte Ibrahim has over 11 years of oncologist industry drug development experience at Merck and GSK. The company is a manufacturer of medicines for the treatment of cancer and other major diseases.
Seeking Alpha · 04/16 07:25
Weekly Report: what happened at IVBIY last week (0408-0412)?
Weekly Report · 04/15 11:36
Weekly Report: what happened at IVBIY last week (0401-0405)?
Weekly Report · 04/08 11:41
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
ProfoundBio, A Seattle-Suzhou ADC Biotech, will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. China Medical System in-licensed povorcitinib, an oral JAK1 inhibitor, for autoimmune and inflammatory dermatologic diseases. Shanghai's Visen Pharma announced plans to stage an IPO on the Hong Kong Exchange.
Seeking Alpha · 04/07 10:30
Weekly Report: what happened at IVBIY last week (0325-0329)?
Weekly Report · 04/01 11:38
Reported Earlier, Innovent Dosed First Participant In Phase 3 Clinical Study Of IBI310 In Combination With Sintilimab For MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
Neoshot is the first Phase 3 clinical trial in China to investigate MSI-H/dMMR colon cancer neoadjuvant immunotherapy. The study will evaluate the safety and efficacy of IBI310 combined with sintilimab. The primary endpoints are complete response rate and event-free survival.
Benzinga · 03/27 06:17
Weekly Report: what happened at IVBIY last week (0318-0322)?
Weekly Report · 03/25 11:41
More
About IVBIY
Innovent Biologics Inc is an investment holding company principally engaged in biopharmaceuticals. The Company and its subsidiaries are engaged in research and development of antibody and protein medicine products, sale and distribution of pharmaceutical products, and provision of consultation and research and development services. The Company's main product is Tyvyt (sintilimab injection), which is used to treat relapsed or refractory classical Hodgkin’s lymphoma. The Company's products also include adalimumab biosimilar IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab biosimilar IBI-305 is used to treat metastatic colorectal cancer and advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). Rituximab biosimilar IBI-301 is used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Its products are used in oncology, metabolic, immunology and ophthalmology diseases.

Webull offers Innovent Biologics Inc stock information, including OTCPK: IVBIY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IVBIY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IVBIY stock methods without spending real money on the virtual paper trading platform.